Drug Trial Radar · NCT04636957
Efficacy and Safety of Ciprofloxacin Plus Fluocinolone Acetonide Otic Solution in the Treatment of Acute Otitis Externa
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
600
Actual
Start
Jan 4, 2021
Primary completion
Oct 17, 2021
Study completion Oct 17, 2021
Sponsor
- Lead sponsor
- Lee's Pharmaceutical LimitedIndustry
- Sponsor type
- Industry
- First posted
- Nov 19, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 3 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase Ⅲ, multicenter, randomized, evaluator-blinded, parallel-group, active-controlled study to assess the efficacy and safety of ciprofloxacin 0.3% plus fluocinolone acetonide 0.025% otic solution vs ciprofloxacin 0.3% otic solution in the treatment of acute otitis externa (AOE), and to assess the pharmacokinetic properties in 12 selected adult subjects. Eligible subjects will be randomized at 1:1 ration to either the treatment arm or control arm. All subject will receive 7 consecutive days of either ciprofloxacin 0.3% plus fluocinolone acetonide 0.025% otic solution or ciprofloxacin 0.3% otic solution alone. The main objectives are to assess the efficacy and safety of ciprofloxacin 0.3% plus fluocinolone acetonide 0.025% otic solution in the treatment of AOE, and to assess the plasma concentration of ciprofloxacin and fluocinolone acetonide after multiple doses of test drug in 12 adult subjects, and evaluate the pharmacokinetic parameters.
Conditions
- Acute Otitis Externa
Interventions
Ciprofloxacin-Fluocinolone Acetonide, 0.3%-0.025% Otic SolutionDrug
0.25mL/vial, each vial contains 0.75mg of ciprofloxacin and 0.0625mg of fluocinolone acetonide.
Ciprofloxacin 0.3% solutionDrug
0.4mL/vial, each vial contains 1.2mg ciprofloxacin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical CureTime frame: End of Study (Visit 4, Day 15+2)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Eye & Ent Hospital of Fudan University
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.